{"name":"Spinogenix","slug":"spinogenix","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tazbentetol","genericName":"Tazbentetol","slug":"tazbentetol","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Tazbentetol","genericName":"Tazbentetol","slug":"tazbentetol","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxOTjNvdGJRTmhEbG8xb3AyR0VPR05TZEZ4dXl0T1BTRjFpLU5LdlVMb2p5dDJBM2RCdzAybGZCZ2N1aGQ1TmlzR3ZqNTV5TTBVbHFSRmw5bWZwY0hpYW13UWR3VVRkcmVjSktLQm0tVHluVzd5bEJ5QWF5cWFnQUo0OTFpZ083a3FvTnk5anE0ajdVcUNLQTZ1QTlYd1lGZExRc2c?oc=5","date":"2025-12-08","type":"trial","source":"Clinical Trials Arena","summary":"Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study - Clinical Trials Arena","headline":"Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOa0wzMURZV3I4ZHNnRU0zZG01V1ZnMEZmanRqbjNwQ0ZiR1R3c3MyaGdXYm1WU3lac09kRUNoYnJBeXAzY0ZiVm5xVS1vMGJzTzI3Rmk2YVBVc0RQOE8xN280UkNFSTVjaVRuQWJmdnVCaEhuOHpwZmp0Q1dVeENrZ1lNMkhRVUF1?oc=5","date":"2025-11-05","type":"trial","source":"Clinical Trials Arena","summary":"Spinogenix’s ALS hopeful to advance to registrational trial - Clinical Trials Arena","headline":"Spinogenix’s ALS hopeful to advance to registrational trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNbU5CWTdhS0FGQ1dIWkVxNGF2X3dtQ0dqcGozYnl2RkJFS3FKMGFrUGhWV0kzZVBITUxCRzBqTl9EcmU0N0ozdlNGVGxwTl9QUTFvZ0tFNXZxTGUtLUt1WjFsUzg3MFZJdWp5akd0aG1heGxsa0tRZUxvdmVzRmtXYVRRZUgwN3FXV01xSFVPN0hfdU1ZOFg0Uzl0Z0RCVks3amc?oc=5","date":"2025-04-07","type":"trial","source":"Pharmaceutical Executive","summary":"Spinogenix Launches Phase II Trial for Synaptic Regenerative Therapy in Schizophrenia - Pharmaceutical Executive","headline":"Spinogenix Launches Phase II Trial for Synaptic Regenerative Therapy in Schizophrenia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTFAzaFJPY3VXWVlaVWRhVVVzTDR3U3Z2dm9ZVnhmdzJ0VHFGSV9sQmk0OTlMZXpkdW9YS0F2VGV2YXR4eXNnd3hKdG11WFRlZVo2cTlyTGNFSmFJNFJhdkFkb3RjQmtIZ3VYSW1wdFlhc0I2d3pmWno3eXdsdVo?oc=5","date":"2024-10-18","type":"pipeline","source":"Life Science Leader","summary":"Companies To Watch: Spinogenix - Life Science Leader","headline":"Companies To Watch: Spinogenix","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPbVRhRHhNQXhESEFkX2dkU2RfdUFXUGZCcTRXaGkwT0ZNMEFtRjduckVySWlaUEhTMDRrOWo4M2g4cFRQMmZ5ZjVucG5QbkQ5UmZlR3NuOTR4cGxkZ0lvUzdlbXZBcE5PY3hwMFJxcmZySmpTejh3aE5MaEVLRF9wZ19pd2FLU0xGT3dkUDRTOVVoeGhsRnFQRFBVa2FtLVJON1haa1p4cF9BS19OSFVoNl9yNVh6UVJxcGJUOXlGdWlTa3M?oc=5","date":"2024-08-01","type":"pipeline","source":"BioSpectrum Asia","summary":"Addressing Root Causes of Brain Disorders with Innovative Therapeutics - BioSpectrum Asia","headline":"Addressing Root Causes of Brain Disorders with Innovative Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxNUVRDTnhDa3ZIak5HYzlENnJwU1R4aXI3WHlfMjNaSmY0MDlReEwzTl9PZW9faDFQc0pwWlp0N1l3NTk1bnFILXd3bm5GOWlBTjNRTVkwLUNoc1NETm9uQ210dzFkTHgyUTY5bW52VnlCcWdnSHcyVnFfZm5ZQ184b1FTa0xTRU9zRmc3R252R3l5TmNHRW1UOGxpMkdGQXlsZFBqR1FZd3Vmd3p1Y0syWC1kQXByNFg3bWpMSm9IYm05bjR1V3pQZGF4U2Q5czVyMFVpQ0NJSzBGOEN0T2xoYmlZOG5BaVQ1dU1lOUhuOE1heEJ6OE9WaFNVRUFUUHpuLVJwX3VZazdmMXJs?oc=5","date":"2021-06-07","type":"regulatory","source":"GlobeNewswire","summary":"Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis - GlobeNewswire","headline":"Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}